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ABSTRACT
Telomerase activity, not detectable in somatic cells
but frequently activated during carcinogenesis,
confers immortality to tumors. Mechanisms govern-
ing expression of the catalytic subunit hTERT, the
limiting factor for telomerase activity, still remain
unclear. We previously proposed a model in which
the binding of the transcription factor CTCF to the
two first exons of hTERT results in transcriptional
inhibition in normal cells. This inhibition is abro-
gated, however, by methylation of CTCF binding
sites in 85% of tumors. Here, we showed that
hTERT was unmethylated in testicular and ovarian
tumors and in derivative cell lines. We demonstrated
that CTCF and its paralogue, BORIS/CTCFL, were
both present in the nucleus of the same cancer
cells and bound to the first exon of hTERT in vivo.
Moreover, exogenous BORIS expression in normal
BORIS-negative cells was sufficient to activate
hTERT transcription with an increasing number of
cell passages. Thus, expression of BORIS was suf-
ficient to allow hTERT transcription in normal cells
and to counteract the inhibitory effect of CTCF in
testicular and ovarian tumor cells. These results
define an important contribution of BORIS to immor-
talization during tumorigenesis.
INTRODUCTION
Telomerase activity is one of the most important factors
that has been linked to multiple developmental processes
including cell proliferation, differentiation, aging and sen-
escence (1,2). This complex enzyme stabilized telomeres
length by adding hexameric repeats (TTAGGG) to telo-
meric ends of linear chromosomes, thus compensating for
the continued erosion of telomeres (3). Maintenance of
telomeres is required for cells to escape from replicative
senescence and proliferate indeﬁnitely. In adult humans,
telomerase activity is not detectable in most somatic cells
(4). In contrast, highly proliferative cells, such as germ
cells and stem cells, and 85–95% of cancers express tel-
omerase (5). Among the various components of human
telomerase, only the telomerase RNA component,
hTERC, and the human telomerase reverse transcriptase,
hTERT, are essential for the reconstitution of telomerase
activity in vitro (6–8). Moreover, it has been shown that
ectopic expression of hTERT is sufﬁcient to restore tel-
omerase activity in telomerase-negative cells (8–10).
Therefore, hTERT expression is deﬁned as the rate-
limiting factor in regulating telomerase activity (11), and
many studies suggest that the regulation of hTERT occurs
primarily at the transcriptional level.
Following the characterization of the hTERT genomic
sequence and gene organization, a minimal promoter en-
compassing a 283 bp region upstream of the initiation
ATG codon and numerous binding sites for transcription
factors have been described (12–15).
The fact that the hTERT promoter lies within a CpG
island has led to studies of transcriptional regulation
through DNA methylation. Contradictory results have
been published (16–21), but apparently hypermethylation
of hTERT is required for its expression in the majority of
telomerase-positive cells (18,22). We previously showed
that the proximal exonic region of hTERT is involved in
transcriptional inhibition of the gene (23) caused by
binding of CTCF to the ﬁrst two exons (24). In fact,
hypermethylation of the hTERT exon 1 region in cancer
cell lines and tumors prevents the binding and the repres-
sive effects of CTCF. In addition, a speciﬁc 110 bp region
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within the core promoter was found to be hypomethylated
in hTERT-expressing cells thereby allowing the transcrip-
tional effect of the minimal promoter (25). A recent study
also demonstrated that this region of the hTERT
promoter upstream of the transcriptional start site is
unmethylated and linked with active chromatin in cancer
cells, thus explaining hTERT activity in the face of hyper-
methylation of the 50 regulatory region (26). Moreover,
Meeran et al. have reported that down-regulation of
DNMTs in response to HDAC inhibition by treatment
with potential cancer-prevention drug Sulforaphane
(SFN) generates site-speciﬁc CpG demethylation primar-
ily in the ﬁrst exon of the hTERT gene, which, in turn,
leads to the repressive recruitment of CTCF to the same
sites we mapped earlier (23,24,27).
Although methylation of its promoter appears to
be the most frequently observed mechanism of the
hTERT gene regulation in tumor tissues and tumor cell
lines (18,20,28), it is obvious that one or more other
methylation-independent mechanisms exist for certain
types of telomerase-positive cells (16,17,19,28–30) includ-
ing testicular and ovarian cancers (19,28). Therefore, a
mechanism that does not require hTERT methylation
must be active in these telomerase-positive and hTERT
umethylated tumors to prevent the repressive effects of
CTCF.
Previous studies shown that BORIS (Brother of the
Regulator of Imprinted Sites), also termed CTCFL
(CTCF-like), is the mammalian paralogue of a highly
conserved (31,32), multi-functional chromatin factor
encoded by the candidate tumor suppressor gene, CTCF
(33–36). BORIS was found to be present mainly in testicu-
lar and has ﬁrst been found to be express in a mutually
exclusive manner with CTCF during male germ cell devel-
opment (37). It has recently been shown to be critical to
normal spermatogenesis in mice, by regulation of the CTS
(Cerebroside Sulfotranscferase) gene (38). In addition to
its normal expression in testis, studies revealed that
various tumors and cancer cell lines, also expressed
BORIS (39–43). BORIS is also involved in epigenetic
reprogramming, both in normal development and in
tumorigenesis (34,37,44). In addition, it has been shown
that conditional expression of BORIS induced expression
of a series of Cancer Testis Antigens (CTA) genes, as
MAGE-A1, NY-ESO-1 (40,42) and SPANX (45).
Althought BORIS and CTCF were shown to bind to the
same recognition sequences, data provided clear demon-
stration that BORIS is functionally different from CTCF
(38). Therefore, BORIS could also bind the CTCF target
site within hTERT exon1.
In this study, we examined the potential contribution of
BORIS to hTERT transcriptional regulation in testicular
and ovarian cancer cells. We ﬁrst analyzed the methyla-
tion pattern of hTERT in primary tumors of these types,
in the NCCIT and OVCAR-3 cell lines, and investigated
the role of BORIS in the hTERT gene regulation.
Our data indicate that expression of BORIS in tumor
cells is permissive for the transcription of hTERT
in spite of the presence of the CTCF repressor. We
concluded that BORIS and CTCF have opposite effects
on hTERT transcription. Moreover, we showed that
expression of BORIS in normal cells is sufﬁcient to
allow hTERT transcription and to extend their lifespan
in vitro, revealing an important role for BORIS in
immortalization.
MATERIALS AND METHODS
Tissue samples and cell lines
Ten testicular and ﬁve ovarian tumors were analyzed. The
use of human tissue samples for this study was according
to the guidelines of the ethical committee of the Medical
Faculty of Lausanne. The human tumor cell lines (HeLa,
cervical adenocarcinoma; NCCIT, testis teratocarcinoma,
OVCAR-3, ovary carcinoma) and normal BJ ﬁbroblast
cells were obtained from the ATCC and were grown in
the medium recommended by the ATCC. HeLa, NCCIT
and OVCAR-3 cell lines are telomerase-positive, whereas
BJ cells are telomerase-negative. The Normal Human
Bronchial Epithelial cell line (NHBE) was obtained from
Lonza (Basel, Switzerland) and maintained in medium
without Retinoic Acid as recommended by Lonza. The
mouse normal ﬁbroblast NIH3T3 cell line was used in
transient transfection experiments and was maintained in
DMEM supplemented with 10% FBS.
DNA methylation analysis
DNA was extracted from cultured cells using the DNeasy
tissue kit (Qiagen, Hilden, Germany). After bisulﬁte modi-
ﬁcation (EpiTect Bisulﬁte, Qiagen, Hilden, Germany),
methylation analysis of the hTERT promoter was done
by ampliﬁcation of a 224 bp fragment (443 to 274
from the ATG translational start site) and analyzed by a
methylation-sensitive single strand conformation assay
(MS-SSCA) as previously described (46). For cell lines,
methylation analysis of the promoter and ﬁrst exon of
hTERT (from 200 to +100) was also performed after
ampliﬁcation of bisulﬁte modiﬁed DNA with the primers
50-CTACCCCTTCACCTTCCAA-30 and 50-GTTAGTTT
TGGGGTTTTAGG-30. Triplicate PCR products were
cloned into the TOPO TA cloning kit (Invitrogen).
Plasmid DNAs were extracted from bacterial clones with
the QIAprep Spin Miniprep Kit (Qiagen). Each clone was
analyzed by sequencing, with the M13 forward primer
(50-GTAAAACGACGGCCAG-30) by the NIAID
sequencing facility.
Plasmid construction and siRNA sequences
hTERT reporters. pTERT–297 contains the hTERT
minimal promoter (23). The pTERT–297/ex1 vector
contains the hTERT minimal promoter and 80 bp of the
ﬁrst exon. To generate this vector, an hTERT fragment
was generated by PCR and cloned into the pGL3 basic
vector (Promega). The pTERT-297/ex1mut contains a
mutated version of the CTCF binding site located in
exon1 (24). All constructs were used in transient transfec-
tion experiments.
BORIS and CTCF expression vectors. In the pCMV-
BORIS and pCMV-CTCF vectors, BORIS cDNA
and CTCF cDNA were cloned in pCMV6-XL4 by
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ORIGENE Technologies (Rockville, MD, USA). A
pBIG-BORIS vector was created on a template containing
the tetracycline-responsive, autoregulated, bidirectional
expression vector pBIG2i (42). The original plasmid was
used as a control. A pBORIS-puro vector contained the
cDNA of BORIS under control of the CMV promoter
and contains the puromycin gene as a selective marker.
The empty vector was used as a negative control in trans-
fection experiments.
siRNA BORIS and CTCF sequences. siRNAs were
ordered from Sigma Life Science. An siRNA sequence
targeting BORIS was: 50-CGAGUUGAUGCCGGAAA
AA[dT]-30 and a siRNA sequence targeting CTCF was:
50-UUGGUUCGGCAUCGUCGUU[dT]-30.
Transient transfection and luciferase assays
Cells were seeded at a concentration of 2 105/3.8 cm2 for
NIH3T3, HeLa, NCCIT and OVCAR-3, and 5 104 cells/
3.8 cm2 for BJ and cultured overnight. Transient transfec-
tions of reporter plasmids (0.75 mg/well) and expression
vector (1 mg/well) were carried out in triplicate using
JetPEI Cationic Polymer Transfection reagent (8 ml/well)
(Polyplus-transfection, Illkirch, France). All experiments
were performed at least twice. The pRL-tk vector
(0.25 mg/well) (Promega, Madison, WI) was co-transfected
as an internal control for transfection efﬁciency in transi-
ent transfection experiments. Luciferase assays were per-
formed using the Dual-Luciferase Reporter Assay System
(Promega, Madison, WI).
NHBE cells were seeded at 3.5 102 cells/cm2 in 60mm
dishes. The day after, cells were transfected using
FUGENE6 3 ml for 2 mg of DNA (Roche, Rotkreuz,
Switzerland) In co-transfection experiments, a reporter:
expression vector ratio of 1:1 was used. Expression of
pBIG-BORIS was induced by two different concentra-
tions of doxycycline: a low concentration of 0.0625 mg/
ml and a high concentration of 1mg/ml.
Co-transfection of expression plasmids and siRNA was
performed in triplicate in six-well-plates for OVCAR-3
and NCCIT cell lines using the jetPRIMETM transfection
reagent (Polyplus-transfection, Illkirch, France) following
the manufacturer’s instructions.
Immunﬂuorescence
HeLa, NCCIT and OVCAR-3 cells were grown for one
day on glass slides in a four-well tissue culture chamber.
Cells were washed in 1 PBS and ﬁxed 10min in 4%
paraformaldehyde/1 PBS solution, freshly prepared.
After two washes with 1 PBS, cells were permeabilized
for 15min in freshly prepared 1 PBS/0.2% Triton
solution. Slides were washed in 1 PBS and then cells
were blocked in a 1 PBS/10% goat serum for 90min.
Rabbit anti-BORIS and mouse anti-CTCF antibodies
(produced by D.L. et al.) were diluted at 1/200 and
1/400, respectively, in antibody diluent solution
(DakoCytomation, Carpinteria, CA) with 0.5M NaCl.
Slides were incubated at 4C overnight. The next
day, cells were washed three times in 1 PBS/1% milk/
0.5% TritonX-100. Secondary antibodies including
FITC-anti-rabbit and Cy3-anti-mouse (Sigma-Aldrich,
St. Louis, MO) were added at a 1/100 diloution in
1PBS and incubated for 1 h at RT in the dark. Cells
were then washed three times in 1 PBS/1% milk/0.5%
TritonX-100 followed by three washes in 1 PBS.
Slides were mounted in 1 PBS/20% glycerol. Images
were analyzed on a confocal microscope (Nikon,
Chiyoda-ku, Tokyo).
RNA extraction and RT–PCR
RNA was extracted from cells using the TRIzol Reagent
(Invitrogen, Basel, Switzerland). Platinum quantitative
RT–PCR Thermoscript one-step system (Invitrogen) was
used to amplify hTERT mRNA as previously described
(24). RT–PCR products were analyzed on 2% agarose
gels.
BORIS expression was screened with the primers
RT-BORIS-FW 50-AAGCCGCGAACGGAGACG
AAG-30 and RT-BORIS-REV 50-ACGCCTTCATCCAC
TTCCTCTTT-30. CTCF expression was screened with the
primers RT-CTCF-FW 50-GTGGCGCGGAGAATGAT
TAC-30 and RT-CTCF-REV 50-TCCACAATGGCTTCG
ACTGC-30. RT–PCR products were analyzed on 2%
agarose gels.
For quantitative RT–PCR, RNA was converted to
cDNA using random primers and superscript III reverse
transcriptase (Invitrogen). Quantitative real-time RT–
PCR (qPCR) analysis was performed using the TaqMan
Universal PCR master Mix (Applied Biosystems, Foster
city, CA) and using the Applied Biosystem 7900HT
Real-Time PCR system. CTCF expression was determined
using the following primers and probe: 50-TGACACAGT
CATAGCCCGAAAA-30 (FW), 50-TGCCTTGCTCAAT
ATAGGAATGC-30 (REV) and 6FAM-TGATTTGGGT
GTCCACTTGCGAAAGC-MGB (probe). Human
Glyceraldehyde-3-phosphate dehydrogenase (hGAPDH),
human BORIS (hBORIS) and human Telomerase
Reverse transcriptase (hTERT) primers/probe mixtures
were purchased as pre-developed assays (Applied
Biosystems, Foster city, CA).
Chromatin immunoprecipitation assay
NCCIT, OVCAR-3 and HeLa cells were used for chroma-
tin immunoprecipitation (ChIP) assays to show the in vivo
binding of CTCF and BORIS on hTERT exon1. We used
a ChIP Assay kit (Upstate, Charlotteville, VA, USA) and
followed the manufacturers’ recommendations. One ChIP
reaction used 10 mg anti-CTCF monoclonal antibodies
previously described (32) or 10 mg of anti-BORIS poly-
clonal antibody (Abcam, Cambridge, UK).
Immunopuriﬁed DNAs were used in qPCR using SYBR
green mix and the following speciﬁc primers for hTERT
exon1: FW 50-GCGGCGCGAGTTTCAG-30 and REV
50-GCAGCACCTCGCGGTAGT-30. The human Nmyc
CTCF binding site was used as positive control for
CTCF binding using the following primers: FW 50-GGC
TCTGTGAGGAGGCAAGGTG-30REV and 50-GCTCT
CTATTTGGAGTGGCGGG-30. Primers used to
co-ampliﬁed immunoprecipitated DNA of hTERT exon1
and H19 after ChIP were previously described (25).
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RESULTS
Testicular and ovarian tumor cells exhibited the same
methylation proﬁle as normal cells
Using the MS-SSCA approach, we analyzed methylation
of 20 CpGs within the hTERT 50 regulatory region
(between 443 and 274) in primary tumor samples
obtained from ﬁve testis and ﬁve ovaries (Figure 1A).
Analyses of the hTERT promoter showed an
unmethylated pattern except for one ovarian tumor that
had a hypermethylated hTERT gene (Figure 1A).
Methylation analysis of the testicular (NCCIT) and the
ovarian (OVCAR-3) tumor cell lines identiﬁed an
unmethylated hTERT 50 regulatory region in contrast
with the hypermethylation observed in the telomerase-
positive HeLa cervical tumor cell line (Figure 1A).
RT–PCR analyses showed that hTERT was expressed in
all of the primary tumors and cell lines regardless of the
methylation proﬁle (Figure 1B). The methylation status of
the hTERT CpG island in NCCIT and OVCAR-3 cell
lines was examined in greater detail around the ATG
within sequences previously shown to be involved in
hTERT regulation (25). Figure 1C presents data from rep-
resentative clones of the HeLa and BJ cell lines as refer-
ence methylation proﬁles from a cancer cell line and a
normal cell line, respectively (24,46). Sequencing of
bisulﬁte-modiﬁed DNA from NCCIT and OVCAR-3
revealed hypomethylation of these regions at levels close
to that observed in the normal cell line BJ, with, respect-
ively, 17% and 0% of methylation within the region B
containing the CTCF binding site. This result contrasted
with data we reported previously for the HeLa cell line. In
NCCIT and OVCAR-3, the mechanism preventing CTCF
binding to the ﬁrst exon of hTERT is thus independent of
DNA methylation and had to involve another mechanism.
The repressor effect of the proximal exonic region of the
hTERT gene is less efﬁcient in testicular and ovarian
tumor cell lines than in HeLa cells
The inhibitory effect of the ﬁrst exon of hTERT on its
minimal promoter was tested in NCCIT and OVCAR-3
and compared to HeLa and BJ ﬁbroblasts. These four cell
lines were transiently transfected with the pTERT-297 and
the pTERT-297/ex1 luciferase reporter vectors containing,
respectively, the hTERT minimal promoter alone or with
hTERT exon 1 (Figure 2A). The transcriptional activity of
the hTERT minimal promoter was different in these four
cell lines, ranging from 16.5 to 88% of relative luciferase
activity in BJ and HeLa cells respectively. Transfection of
the pTERT-297/ex1 construct resulted in a 6-fold dimin-
ution of luciferase activity in HeLa cells. Interestingly, this
reduction was only 3-fold and 2.3-fold in NCCIT and
OVCAR-3, respectively (Figure 2B). It is interesting to
note that in BJ, the low activity of the reporter vector
containing the hTERT minimal promoter was completely
inhibited by the addition of the ﬁrst exon containing the
CTCF binding site. Therefore, in NCCIT and OVCAR-3
cell lines, the inhibitory effect of CTCF on hTERT
minimal promoter transcription was less efﬁcient than in
HeLa cells, showing that cellular representation of
transcription factors were distinct and might differentially
inﬂuence hTERT expression.
CTCF and BORIS were co-expressed in the testicular
and ovarian tumor cell lines
As BORIS, a paralogue of CTCF, is expressed in male
germ cells, we investigated the expression of these two
factors in NCCIT and OVCAR-3. RT–PCR analyses of
CTCF and BORIS transcripts showed that these two
factors are expressed in both lines (Figure 3A). In
normal cells, BORIS and CTCF were found to be ex-
pressed in a mutually exclusive manner (37). This
prompted us to investigate the expression of these two
proteins by immunoﬂuorescence in NCCIT, OVCAR-3
and HeLa. These studies showed that BORIS and
CTCF were coexpressed in the nuclei of NCCIT and
OVCAR-3 (Figure 3B, a–f). In HeLa cells, CTCF was
localized in the nucleus, whereas BORIS could be
detected only at background levels (Figure 3B, g–i). In
NCCIT and OVCAR-3, the merger of CTCF and
BORIS signals showed that BORIS is likely localized in
the nucleus where it could compete with CTCF.
BORIS and CTCF bound in vivo to the same region of
the hTERT gene
As the BORIS protein has the same 11 zinc ﬁnger domain
as CTCF (34,37), we investigated the hypothesis that
BORIS can replace CTCF on hTERT repressive site(s),
thus allowing hTERT expression. Consequently, we
studied in vivo binding of CTCF and BORIS to hTERT
exon 1. Quantitative ChIP assays conﬁrmed that CTCF
did not bind the exon 1 of hTERT in HeLa cells in vivo,
whereas it did bind exon 1 of hTERT in OVCAR-3 and
NCCIT cells with a 3.6- and 2.2-fold change respectively
(Figure 4A). Similarly, BORIS bound to the ﬁrst exon of
hTERT in OVCAR-3 and NCCIT cells but not in HeLa
cells (Figure 4A). These results indicated that BORIS and
CTCF can bind the same region of hTERT in the
telomerase-positive cell lines OVCAR-3 and NCCIT.
These results were conﬁrmed by ChIP analyzed on
agarose gels (Figure 4B and C) as described previously
(24,25).
BORIS and CTCF expression levels modulated hTERT
transcription
The ﬁnding that CTCF and BORIS bound hTERT exon1
in vivo, prompted us to examine the effect of BORIS
downregulation on hTERT transcription. First we
co-transfected NCCIT and OVCAR3 cells with reporter
plasmids containing the hTERT minimal promoter and
the ﬁrst exon with siRNA against BORIS. The data in
Figure 5A showed that a decrease in BORIS expression
induced a decrease of reporter activities in both cell lines.
These results demonstrated that BORIS acted as an in-
hibitor of the hTERT minimal promoter in transient
transfection experiments. Because the use of reporter
vectors did not fully reﬂect hTERT transcription in vivo,
we performed additional transfection experiments in
OVCAR-3. Then we modulated the balance between
BORIS and CTCF expression levels using speciﬁc
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siRNAs against BORIS and CTCF. The endogenous
levels of hTERT, BORIS and CTCF were then quantiﬁed
by qPCR. Transcript levels in siRNA-treated cells were
normalized to the levels detected after transfection with
a scrambled siRNA. A 2-fold decrease in BORIS tran-
scripts was observed in cells transfected with siRNA
against BORIS and levels of CTCF transcripts were
decreased by 30%. In contrast, levels of hTERT tran-
scripts were essentially unchanged. (Figure 5B). A
2.5-fold decrease in CTCF transcripts was observed in
cells transfected with siRNA against CTCF while levels
of BORIS and hTERT transcripts were unaffected.
These results demonstrated that control of BORIS and
CTCF transcription were closely linked such that modu-
lation of one could affect the expression of the other.
In a second experiment, we overexpressed CTCF
in OVCAR-3 cells and measured the transcript level
of endogenous hTERT and BORIS using levels in
unmanipulated cells referenced as 100%. Overexpression
of CTCF resulted in increased BORIS transcription, but
had no effect on the transcriptional levels of hTERT
(Figure 5C). This suggests that the predicted repressive
effect on hTERT of increased CTCF expression was coun-
tered by the increase in BORIS expression, thereby
indicating that transcription of hTERT cannot be re-
pressed by CTCF in cells that also express BORIS.
Taken together, these results demonstrated that the equi-
librium between the levels of CTCF and BORIS
expression have a great importance for regulating
hTERT transcription.
In studies of HeLa cells that do not express BORIS, a
reporter vector with a mutated CTCF binding site in
exon1 exhibited increased hTERT promoter activity.
Parallel studies of BORIS-positive OVCAR-3 cells
revealed that the mutation had no effect on hTERT
promoter activity (Figure 5D). This experiment showed
that in BORIS-negative cells, mutation of the CTCF
binding site diminished the inhibitory effect of CTCF on
hTERT promoter, and that in BORIS-positive cells, the
presence of BORIS maintained hTERT promoter activity
in the presence of CTCF.
Expression of BORIS induced hTERT transcription in
telomerase-negative cells
To further investigate the contributions of BORIS
to hTERT transcriptional activation, NIH3T3 cells
were co-transfected with a BORIS expression vector
(pBIG-BORIS) and hTERT reporter constructs.
Expression of BORIS was induced with doxycycline and
luciferase activities were measured 24 h after transfection.
The level of reporter activity of pTERT-297, which
contains only the hTERT minimal promoter, was set as
the reference point of 100%. The activity of the
pTERT-297/ex1 vector was 2.5-fold lower in NIH3T3
cells co-transfected with the empty vector. In the
co-transfection experiments with pBIG-BORIS, the
reporter activity of pTERT-297/ex1 reporter activity was
only 1.5-fold lower (Figure 6A), a level similar to that
observed in OVCAR-3 cells transfected with
pTERT-297/ex1 (Figure 2B). To conﬁrm the stimulating
effect of BORIS on hTERT transcription, the
pCMV-BORIS expression vector was transfected in the
BJ normal human ﬁbroblast cells that do not express
either BORIS or hTERT. After transfection with the
pCMV-BORIS vector, BORIS and hTERT transcripts
were easily detected by RT–PCR (Figure 6B). We also
performed RT–PCR assays for the full-length and the
a-spliced variants of hTERT (24). The ampliﬁed BORIS
fragment obtained from BJ cells transfected with
pCMV-BORIS was puriﬁed and directly sequenced, re-
vealing the presence of only the full-length hTERT tran-
script (data not shown). In addition, qPCR analysis
showed that high levels of BORIS transcripts were
associated with substantial expression of hTERT while
expression of CTCF was unchanged (Figure 6C).
Expression of BORIS in NHBE cells induced expression
of hTERT and promoted cell viability
The lifespan of Normal Human Bronchial Epithelial cells
(NHBE) in culture is very limited such that after 5
passages, virtually all cells detach and die. NHBE cells
were transiently transfected with either a BORIS expres-
sion vector or an empty vector and BORIS expression was
induced with doxycycline. After days 4, 7 and 10, the
cultures were split. Half the cells were returned to
culture and the other half was used for RNA extraction
and qPCR to quantify BORIS and hTERT transcripts
(Figure 7). Between Days 7 and 10, cells transfected with
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Figure 2. Transcriptional activity of the hTERT minimal promoter
with or without the proximal exonic region. (A) Schematic representa-
tion of the luciferase reporter plasmids pTERT-297 and pTERT-297/
ex1. (B) Luciferase reporter plasmids containing the hTERT minimal
promoter, without (pTERT-297) or with (pTERT-297/ex1) the
proximal exonic region, are transfected into HeLa, BJ, NCCIT and
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Nucleic Acids Research, 2011, Vol. 39, No. 3 867
empty vector detached and died. At Day 10, cells trans-
fected with the BORIS expression vector exhibited high
levels of BORIS and hTERT transcripts. Lower levels of
both BORIS and hTERT transcripts observed at Day 7
could be explained by plasmid dilution occurring with cell
growth. The difference between the levels of BORIS tran-
scripts at days 4 and 10 was 6-fold with 0.625 mg/ml of
doxycycline and 55-fold with 1 mg/ml doxycycline. It is
interesting to note that a low or a high concentration of
doxycycline did not signiﬁcantly affect the levels of
BORIS transcripts at Day 4 while the levels of hTERT
transcripts were almost 2-fold lower with the higher con-
centration of the drug. These observations lead us to
suspect that a high level of BORIS transcripts were not
necessarily associated with high levels of active BORIS
protein. At Day 10, as we considered that plasmids were
integrated, the levels of BORIS transcripts were 10-fold
higher with a high concentration of doxycyline than with a
low concentration (Figure 7). The levels of hTERT tran-
scripts detected at low concentration of doxycycline did
not differ at Days 4 or 10. With a high concentration of
doxycycline, however, hTERT transcripts were 28-fold
higher at Day 10 than at Day 4. Cells kept in continuous
culture after day10 were viable for two more weeks, but
then they stopped proliferating and ﬁnally detached. As
we had found that low or high levels of BORIS transcripts
affected the levels of hTERT transcripts after 10 days, the
same experiments were performed using the non-inducible
pBORIS-puro vector with similar results; the cells ﬁnally
stopped proliferating and detached (data not shown).
DISCUSSION
Our studies of hTERT regulation in testicular and ovarian
tumors showed that the presence of unmethylated CTCF
repressor sites in the gene were not inhibitory to transcrip-
tion raising the question as to how these cancers, despite a
normal methylation proﬁle, can express hTERT. Here we
describe a novel mechanism that disrupts CTCF repres-
sion of hTERT—occupancy of the CTCF binding sites by
BORIS. Since BORIS has the same DNA binding domain
as CTCF and is known to be expressed at a high level in
testis (37,38), in oocytes (47), as well as in various tumors
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and cancer cell lines (39–43), we investigated its potential
role in the regulation of hTERT in testicular and ovarian
cancers. Analysis of testicular and ovarian cancer tissues
showed, at the exception of one ovarian cancer, the
hTERT promoter was hypomethylated, that is in correl-
ation with what was observed in a previous study (28).
Parallel studies of the same 50 regulatory region of
hTERT in OVCAR-3 and NCCIT cell lines showed they
were also hypomethylated. A more detailed bisulﬁte
analysis of the promoter and exon 1 regions of hTERT
in NCCIT and OVCAR-3 cell lines showed they were
unmethylated as in normal cells, ﬁndings that contrast
with the hypermethylated state of these sequences in the
HeLa carcinoma cell line, that reﬂected the hTERTmethy-
lation proﬁle in most cancer cells (16–18,20).
In transient transfection experiment using HeLa cells, it
was shown that the activity of a reporter containing only
the minimal hTERT promoter was 6-fold higher than the
activity of a reporter containing the minimal promoter
together with the ﬁrst exon. In BJ cells, the reporter con-
taining the minimal promoter and the exon 1 of hTERT
did not exhibit any activity, most likely due to the absence
of factor(s) essential for activation of the hTERT minimal
promoter. In the same experiment, we showed that the
activities of reporters containing the minimal promoter
and the exon 1 were 2- to 3-fold higher in NCCIT and
OVCAR-3 than in HeLa cells. It is noteworthy that these
two tumor telomerase-positive cell lines expressed rela-
tively high level of BORIS transcripts. Therefore, the in-
hibitory effect of hTERT exon 1 in reporter assays was less
pronounced in BORIS-positive cells than in HeLa or BJ
cells. The levels of BORIS expression is correlated with
reduced inhibitory effects of the ﬁrst exon of the hTERT
gene. Similarly, co-transfection of a BORIS expression
and hTERT reporter vectors in NIH3T3 cells revealed a
reduced inhibitory effect of the ﬁrst exon on its promoter
activity. Indeed, when BORIS was transiently expressed in
NIH3T3 cells, the reduction in luciferase activity observed
with the hTERT exon1 reporter was less pronounced
compared to the activity resulting in co-transfection
of hTERT exon1 reporter with the empty vector.
Moreover, this activity was close to that observed in the
both BORIS-positive cell lines NCCIT and OVCAR-3.
We also showed that transfection of telomerase-negative
normal ﬁbroblast BJ cells with a BORIS expression vector
was sufﬁcient to induce transcription of the endogenous
hTERT gene. These results demonstrated that BORIS has
the opposite effect of CTCF on hTERT transcription.
BORIS might counteract the repressive effect of CTCF
by binding the target sequences in the hTERT gene thereby
permitting transcription of the hTERT promoter.
Moreover, NHBE cells transfected with BORIS exhibited
active transcription of hTERT and the lifespan of trans-
fected cells was prolonged.
BORIS and CTCF were found to be coexpressed in the
nuclei of NCCIT and OVCAR-3 cells and both proteins
bound to the ﬁrst exon of hTERT in vivo. Thus in NCCIT
and OVCAR-3 cells, CTCF and BORIS might compete
for the same binding sites in the hTERT gene. We
demonstrated in vitro that downregulation of BORIS
in NCCIT or OVCAR-3 was associated with reduced
hTERT minimal promoter activity. However, experiments
measuring the endogenous levels of hTERT after
downregulation of BORIS did not lead to the same con-
clusion. Indeed, the levels of hTERT transcripts were not
signiﬁcantly different. This could be explained by the facts
that (i) BORIS expression was reduced by only 50% and
(ii) downregulation of BORIS was also associated with
downregulation of CTCF. Conversely, overexpression of
CTCF was associated with increased levels of BORIS
transcripts. Taken together, these results demonstrated
that BORIS or CTCF expression could inﬂuence levels
of each other in cancer cell lines. To further examine the
effects of reduced BORIS expression on hTERT transcrip-
tion, we performed serial siRNA transfections and
observed massive cell death. Similar observations were
made in recent studies showing that downregulation of
BORIS by siRNA induced apoptosis in a breast cancer
cell line (48). These results suggest that disturbances of
the equilibrium between CTCF and BORIS in these cells
might induce cell death. In order to avoid deregulation of
the balance between CTCF and BORIS, we performed
transient transfection of hTERT luciferase reporters con-
taining or lacking exon1 of hTERT with or without
mutation of the CTCF binding site. In HeLa cells,
where BORIS levels are low, when we expressed hTERT
with a mutant CTCF target site, we observed an increase
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Chromatin ImmunoPrecipitation (ChIP) Assays were performed in
HeLa, NCCIT and OVCAR-3 cell lines. After immunoprecipitation
with serum or speciﬁc antibodies against CTCF or BORIS, DNAs
were puriﬁed and ampliﬁed by PCR and quantitative PCR. (A)
Quantitative PCR were preformed to amplify the exon1 of hTERT.
Bars represent the mean value of three independent experiments.
(B) PCR coampliﬁcation of the hTERT exon1 and H19 from
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in luciferase activity, indicating that CTCF cannot bind
this site, its inhibitory effect is diminished. In contrast,
parallel studies of the BORIS-positive cell line
OVCAR-3 revealed that luciferase activity was the same
in cells bearing the normal or mutant CTCF binding site.
There are multiple explanations to the observation but
most feasible that BORIS isoforms that have different
Zinc Finger composition can bind to minimal promoter
of hTERT (E.Pugacheva et al., submitted elsewhere). The
mechanism by which BORIS counteracted the inhibitory
effect of CTCF on the hTERT transcription resulting
in activation of hTERT transcription in testicular and
ovarian cancers has to be elucidated. However, such
mechanism involving CTCF and other proteins
counteracting its effect on hTERT transcription has
already been suggested recently. Indeed, in lymphoid
cells, the PAX5 and CTCF factors bound simultaneously
the hTERT exon 1. In this situation, PAX5 might antag-
onize the chromatin-mediated transcriptional repression
by CTCF on hTERT promoter (30).
Since recent studies have shown that hTERT is an
endogeneous inhibitor of the mitochondrial pathway of
apoptosis (49), our data might explain how BORIS acts
as inhibitor of apoptosis in cancer cells by activating
hTERT transcription.
Taken together, these ﬁndings show the importance of
BORIS for transcriptional activation of hTERT and,
possibly, to the process of immortalization during
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carcinogenesis. As CTCF binds directly to SIN3A, which
recruit histone deacetylase and thus prevents transcription
(50), we hypothesize that BORIS might have the opposite
effect and open chromatin around the transcriptional start
site of hTERT. This opening would then allow other
factors to activate the hTERT transcription. Moreover,
recent studies showed that down-regulation of DNMT
by anti-cancer drug or TSA, induced a demethylation of
hTERT exon1 within the CTCF binding site, allowing
binding of CTCF and inhibition of hTERT (27,51). In
addition, downregulation of DNMT also induced an
increase in CTCF binding on BAG-1 oncogene
promoter, while an overexpression of DNMT led to
increase in BORIS binding (52). This opposite behavior
is further reﬂected by changes in H3K4Me2 and
H3K9me2 ratio. Taking together these studies showed
that promoters regulation by CTCF/BORIS involved
epigenetic changes.
In tumors, co-expression of CTCF and BORIS could be
directly responsible for epigenetic deregulation leading to
cancer (34). The demonstrated utility of BORIS as a target
for immunotherapy (53,54) is consistent with the import-
ance of BORIS in carcinogenesis. The importance of
BORIS for hTERT activation suggests that it might be
an essential factor in the immortalization of testicular
and ovarian cancer cells, possibly opening new ways
to understanding of carcinogenesis and for potential
anti-cancer therapies.
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